Effects on Reperfusion Injury of Adding Diltiazem to Tepid Blood Cardioplegia

Authors

  • Hafize Yaliniz
  • Acar Tokcan
  • Handan Zeren
  • Tümer Ulus
  • Bulent Kisacikoglu
  • Orhan Kemal Salih
  • Mehmet Sah Topcuoglu
  • Hakan Poyrazoglu
  • Cumhur Alhan

DOI:

https://doi.org/10.1532/HSF98.20041074

Abstract

Background: Although the present techniques of myocardial preservation for limiting ischemia/reperfusion injury in open heart operations yield excellent results for most patients, certain subgroups of patients with advanced coronary artery disease present a challenge in terms of intraoperative safety.

Methods: In a prospective, randomized, controlled study, we assessed the myocardial protective effects of a total dose of 150 ± 150 = 300 3g/kg diltiazem added to induction and terminal (reperfusion) doses of tepid blood cardioplegia. We determined the myocardial morphological (ultrastructural) and enzymatic (serum assays for the cardiospecific isoenzyme of creatine kinase [CK-MB]) changes and functional recovery (atrioventricular [AV]-node recovery time and postoperative need for inotropic support) in patients undergoing elective coronary artery bypass operations. The determinations were made with respect to values for control patients, who received the same cardioplegia but without the addition of diltiazem.

Results: The mean isoenzyme CK-MB levels and semiquantitative ultrastructural score values of the diltiazem group were significantly less than those of the control group. Although AV-node recovery time was significantly prolonged (P < .05), this factor did not have major clinical impact. Conclusions: We concluded that the addition of 150 ± 150 3g/kg diltiazem to the induction and terminal doses of tepid cardioplegia enhanced myocardial protection in elective aortocoronary bypass surgery in high-risk patients and presented no significant additional operative risk.

References

Adams JE 3rd, Abendschein DR, Jaffe AS. 1993. Biochemical markers ofmyocardial injury: is MB creatine kinase the choice for the 1990s? Circulation 88:750-63.nFlameng W, Borgers M, Daenen W, Stalpaert G. 1980. Ultrastructural and cytochemical changes by cardiac hypothermia in man. J Thorac Cardiovasc Surg 79:413-24.nGrondin CM, Power JL, Vouhe PR, Mebert Y. 1983. Cold cardioplegia with diltiazem, a calcium channel blocker, during coronary revascularization [abstract]. J Cardiovasc Surg 24:291.nGrover GJ, Sleph PG. 1989. Dissociation of cardiodepression from cardioprotection with calcium antagonist diltiazem protects ischemic rat myocardium with a lower functional cost a compared with verapamil or nifedipine. J Cardiovasc Pharmacol 140;331-40.nKröner A, Seitelberger R, Schirnhofer J, et al. 2002. Diltiazem during reperfusion preserves high energy phosphates by protection of mitochondrial integrity. Eur J Cardiothorac Surg 21:224-31.nLathrop DA, Valle-Aguilera JR, Millard RW, et al. 1982. Comparative electrophysiologic and coronary hemodynamic effects of diltiazem, nisoldipine and verapamil on myocardial tissue. Am J Cardiol 49:613-21.nSchaper J, Hehrlein F, Schlepper M, Thiedemann KU. 1977. Ultrastructural alterations during ischemia and reperfusion in human hearts during cardiac surgery. J Mol Cell Cardiol 9:175-89.nTeoh KH, Chribtakis GT, Weissel R, et al. 1986. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia. J Thorac Cardiovasc Surg 91:88-95.nAllen BS, Okatomo F, Buckberg GD, et al. 1986. Reperfusate composition: benefits of marked hypocalcemia and diltiazem on regional recovery. J Thorac Cardiovasc Surg 2:564-72.nBarner HB, Swartz MT, Joseph BS, et al. 1987. Diltiazem as an adjunct to cold blood potassium cardioplegia: a clinical assessment of dose and prospective randomization. Ann Thorac Surg 43:191-7.nBourdillon PD, Poole-Wilson PA. 1980. Effects of verapamil and cardioplegia on calcium exchange and mechanical function in myocardialischemia. Circulation 92(suppl):3-31.nChambers DJ. 2003. Mechanisms and alternative methods of achieving cardiac arrest. Ann Thorac Surg 75:661-6.nChocron S, Kaili D, Yan Y, et al. 2000. Intermediate lukewarm (203) antegrade blood cardioplegia compared with cold and warm blood cardioplegia. J Thorac Cardiovasc Surg 119:610-6.nChristakis GT, Fremes SE, Weisel RD, et al. 1986. Diltiazem cardioplegia: a balance of risk and benefit. J Thorac Cardiovasc Surg 91:647-61.nCohen G, Borger MA, Weissel RD. 1999. Intraoperative myocardial protection: current trends and future perspectives. Ann Thorac Surg 68;1995-2001.nYamamato F, Manning AS, Braimbridge MV, Hearse DJ. 1983. Cardioplegia and slow calcium channel blockers: studies with verapamil. J Thorac Cardiovasc Surg 86:552-61.nZografos P, Watts JA. 1990. Shifts in calcium in ischemia and reperfused rat hearts: a cytochemical and morphometric study of the effects of diltiazem. Am J Cardiovasc Pathol 3:155-65.n

Published

2005-01-04

How to Cite

Yaliniz, H., Tokcan, A., Zeren, H., Ulus, T., Kisacikoglu, B., Salih, O. K., Topcuoglu, M. S., Poyrazoglu, H., & Alhan, C. (2005). Effects on Reperfusion Injury of Adding Diltiazem to Tepid Blood Cardioplegia. The Heart Surgery Forum, 7(5), E434-E439. https://doi.org/10.1532/HSF98.20041074

Issue

Section

Articles

Most read articles by the same author(s)